Financials in USD. Standardized financial statements.
A compact view of how Plus Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $5.21M | $5.82M | $4.91M | $224,000 | $0 | $303,000 | $7.00M | $2.98M | $6.41M | $11.38M |
| Revenue Growth? | -10.5% | +18.5% | +2093.3% | 0.0% | -100.0% | -95.7% | +134.6% | -53.5% | -43.7% | 0.0% |
| Cost of Revenue? | $445,000 | $852,000 | $9.69M | $712,000 | $66,000 | $2.70M | $0 | $1.15M | $1.32M | $2.71M |
| Gross Profit? | $4.77M | $4.97M | -$4.78M | -$488,000 | -$66,000 | -$2.40M | $7.00M | $1.83M | $5.09M | $8.66M |
| Gross Margin? | +91.5% | +85.4% | -97.2% | -217.9% | 0.0% | -791.1% | +100.0% | +61.5% | +79.4% | +76.1% |
| Operating Expenses? | $20.07M | $19.67M | $8.54M | $19.22M | $12.43M | $7.19M | $10.65M | $10.77M | $25.78M | $28.37M |
| Operating Income? | -$15.30M | -$14.70M | -$13.32M | -$19.71M | -$12.49M | -$9.58M | -$3.66M | -$8.76M | -$20.68M | -$19.71M |
| EBITDA? | -$14.85M | -$8.40M | -$12.69M | -$18.85M | -$12.05M | -$8.44M | -$532,000 | -$6.58M | -$18.49M | -$18.27M |
| Income Before Tax | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -$13.40M | -$8.24M | -$3.28M | -$8.88M | -$22.69M | -$22.05M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -$13.40M | -$8.24M | -$10.89M | -$12.63M | -$22.69M | -$22.05M |
| EPS? | $-7.19 | $-48.75 | $-106000.00 | $-288750.00 | $-444500.00 | $-697500.00 | $-3101250.00 | $-32617500.00 | $-131345500.00 | $-240000000.00 |
| Diluted EPS? | $-7.19 | $-58.50 | $-106000.00 | $-288750.00 | $-444500.00 | $-697500.00 | $-3452500.00 | $-32617500.00 | $-131345500.00 | $-240000000.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality